RxDoctor Payments Data

Christa Duff, APRN

Nurse Practitioner · Hazard, KYNPI 1295201432

Payments from drug & device makers

$4,122in general payments, 2019–2025

Across 208 payments — averaging $19.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Gilead$589
  • Johnson & Johnson$509
  • Takeda Pharmaceuticals U.S.A., Inc.$398
  • Sanofi$238
  • Madrigal Pharmaceuticals$213
  • plus $850 from 17 others

What the payments were for

  • Food & beverage$4,02298%
  • Education$1002%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,122 in reported general payments places this provider in the 85th percentile of 1,918 nurse practitioner providers in Kentucky.

See all nurse practitioner providers in Kentucky

Medicare billing

Part B allowed, 2024
$1,386
Medicare patients
19
Services billed
19

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide102$61,702
CreonLipase/Protease/Amylase17$10,893
Sucralfate58$5,654
Mesalamine ErMesalamine14$4,946
Ondansetron Hcl18$3,383
Colestipol Hcl67$2,181
Pantoprazole Sodium150$893
Lactulose21$709
ConstuloseLactulose18$499
Famotidine82$339
Dicyclomine Hcl31$337
EnuloseLactulose12$264
Spironolactone28$255
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl11$176
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl11$171

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$1,325$72,594119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,918 nurse practitioner providers in Kentucky.

Other nurse practitioner in Hazard

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →